...
首页> 外文期刊>Diabetes, obesity & metabolism >Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus - a retrospective nationwide study
【24h】

Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus - a retrospective nationwide study

机译:联合降钙素类药物和二甲双胍联合治疗与二甲双胍和磺脲类药物联合治疗2型糖尿病的心血管安全性-一项回顾性全国研究

获取原文
获取原文并翻译 | 示例
           

摘要

AimDipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists are widely used in combinations with metformin in the treatment of type 2 diabetes; however, data on long-term safety compared with conventional combination therapies are limited.
机译:AimDepteptidyl peptidase-4(DPP-4)抑制剂和胰高血糖素样肽1(GLP-1)激动剂已与二甲双胍联合用于治疗2型糖尿病。然而,与传统联合疗法相比,长期安全性数据有限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号